The purpose of this study is to evaluate the effect of tozorakimab as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.
0 Primary · 15 Secondary · Reporting Duration: by Day 60
Experimental Treatment
Non-Treatment Group
2352 Total Participants · 2 Treatment Groups
Primary Treatment: Tozorakimab · Has Placebo Group · Phase 3
Age 18 - 18 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: